Candesartan cilexetil/rosuvastatin - Alvogen

Drug Profile

Candesartan cilexetil/rosuvastatin - Alvogen

Alternative Names: Candesartan cilexetil/rosuvastatin calcium; DP R208; Rosuvastatin/candesartan

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alvogen
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Fluorobenzenes; Heart failure therapies; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension
  • Phase I Cardiovascular disorders

Most Recent Events

  • 01 Oct 2016 Alvogen Korea completes a phase III trial in Hypertension in South Korea (PO) (NCT02770261)
  • 31 May 2016 Alvogen Korea completes a phase I pharmacokinetics trial in Healthy male volunteers in South Korea (unspecified route) (NCT02709187)
  • 10 Mar 2016 Alvogen Korea plans a phase I pharmacokinetics trial in Healthy male volunteers in South Korea (unspecified route) (NCT02709187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top